CompletedNCT05304364
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
Interventional studyAges 18–50AustraliaAddiction
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- AdelaideSee all locations and recruitment
Study information
Study start dateStarted: March 22, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 10
- Sponsor
- Delpor, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- COMBINATION_PRODUCT
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Australia
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT05304364
- Official title
Show the full official title
Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching From Oral Naltrexone HCL to DLP-160 (Naltrexone Implant) to Intramuscular Vivitrol®
Get this study by email
Recruitment & locations
CompletedAdelaide
Questions about this study
Who is behind this study?
The study sponsor is Delpor, Inc.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A Pharmacokinetic and Safety Study of the Chrono Nicotine Replacement Therapy System in male smokers.
A randomised controlled trial of unsupervised buprenorphine-naloxone versus wait list contol for heroin addiction